Immune checkpoint molecules like PD-1 (programmed death-1) and CTLA-4 (Cytotoxic T lymphocyte-associated antigen-4) function as negative regulators of immune activation, and when triggered by tumor or tumor-associated cells, they suppress immune responses (105, 125128)
Scientific work with Retatrutide may help evaluate how GIP receptor activity contributes to broader incretin and endocrine network behavior, especially when it occurs alongside GLP-1 and glucagon receptor engagement
Differential diagnoses to consider include pre-existing osteoarthritis exacerbated by increased activity, fibromyalgia, vitamin D deficiency, thyroid dysfunction, or other rheumatological conditions
Your provider should review all current medications, supplements, and medical conditions to identify potential interactions beyond aspirin and semaglutide alone
[] Interestingly, over the past decade, multiple case series and long-term data led to its reclassification into a malignant tumor
Frequently Asked Questions Do I have to stay on GLP-1 therapy forever
